Ryan Iarrobino joins Syntimmune from Dyax Corp., where he served most recently as vice president of clinical development. During eight years at Dyax, Ryan held various key roles executing clinical programs, including the program leading to the approval of Kalbitor, a treatment for hereditary angioedema. He built the clinical group that conducted the early-phase program for DX-2930, a fully-human monoclonal antibody for the prevention of hereditary angioedema attacks. DX-2930 received Fast Track, Orphan Drug and Breakthrough Therapy designations from the U.S. Food and Drug Administration.